Search Results
10
Everything
Search Filters
Organization
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
February 26, 2025 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
February 25, 2025 08:05 ET
|
Terns Pharmaceuticals, Inc.
TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 New TERN-701 data from ongoing U.S. healthy volunteer PK study...
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
February 24, 2025 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
February 20, 2025 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 05, 2025 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
February 03, 2025 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
January 02, 2025 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
December 03, 2024 07:00 ET
|
Terns Pharmaceuticals, Inc.
Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels Encouraging safety profile with no dose limiting toxicities,...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
December 02, 2024 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...